首页> 美国卫生研究院文献>Postgraduate Medical Journal >Present treatment options for atrial fibrillation
【2h】

Present treatment options for atrial fibrillation

机译:目前房颤的治疗选择

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Atrial fibrillation is the commonest sustained cardiac arrhythmia. It accounts for >35% of all hospital admissions for cardiac arrhythmias in the United States. The presence of atrial fibrillation increases the mortality of a population by up to twofold. The risk of stroke increases from 1.5% in patients with atrial fibrillation from 50–59 years of age to up to 23.5% for such patients aged 80–89 years. Although the diagnosis of atrial fibrillation is usually straightforward, effective treatment is not. This article will discuss how rhythm control of atrial fibrillation can best be achieved, the controversy over the rhythm versus rate control, the maintenance of sinus rhythm with antiarrhythmic drugs after cardioversion, and prevention of thromboembolism. Finally, the recent advances in various non-pharmacological approaches for the treatment of atrial fibrillation will be highlighted.
机译:心房颤动是最常见的持续性心律不齐。在美国,它占所有心律不齐住院人数的35%以上。心房颤动的存在使人群的死亡率增加了两倍。从50-59岁的房颤患者中风的风险从1.5%增加到80-89岁的此类患者最高23.5%。尽管房颤的诊断通常很简单,但有效的治疗却并非如此。本文将讨论如何最好地实现心房纤颤的节律控制,关于节律与速率控制的争论,复律后抗心律失常药物维持窦性心律以及预防血栓栓塞。最后,将强调在治疗房颤的各种非药物学方法中的最新进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号